Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.97% | -4.02% | -2.45% | 0.91% | 3.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.97% | -4.02% | -2.45% | 0.91% | 3.95% |
| Cost of Revenue | -8.01% | -14.12% | -11.54% | -7.03% | -0.43% |
| Gross Profit | 2.72% | 4.23% | 5.08% | 7.61% | 7.63% |
| SG&A Expenses | 0.81% | -1.33% | -1.46% | -1.00% | 1.13% |
| Depreciation & Amortization | -8.83% | -5.46% | 9.58% | 27.42% | 50.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.48% | -8.06% | -5.80% | -2.55% | 2.48% |
| Operating Income | 10.46% | 16.84% | 15.02% | 20.31% | 11.92% |
| Income Before Tax | -39.63% | 37.89% | 36.67% | 43.23% | 39.64% |
| Income Tax Expenses | -30.79% | 49.15% | 39.57% | 47.01% | 29.40% |
| Earnings from Continuing Operations | -41.97% | 34.88% | 35.84% | 42.17% | 42.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.97% | 34.88% | 35.84% | 42.17% | 42.64% |
| EBIT | 10.46% | 16.84% | 15.02% | 20.31% | 11.92% |
| EBITDA | 6.12% | 11.25% | 12.36% | 18.47% | 15.23% |
| EPS Basic | -38.95% | 42.51% | 41.49% | 45.80% | 44.10% |
| Normalized Basic EPS | 6.56% | 20.99% | 12.20% | 12.65% | 15.30% |
| EPS Diluted | -39.03% | 43.25% | 42.27% | 47.02% | 44.92% |
| Normalized Diluted EPS | 7.10% | 21.64% | 12.93% | 13.40% | 15.95% |
| Average Basic Shares Outstanding | -6.26% | -5.53% | -4.04% | -2.33% | -0.74% |
| Average Diluted Shares Outstanding | -6.75% | -6.04% | -4.63% | -2.97% | -1.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |